Connecticut legislation · 2025 General Assembly
Connecticut SB1473: AN ACT REQUIRING MEDICAID COVERAGE FOR FDA-APPROVED GENE THERAPIES TO TREAT SICKLE CELL DISEASE.
Status: Chaptered, June 23, 2025
What the bill says
An act requiring medicaid coverage for fda-approved gene therapies to treat sickle cell disease. assembly convened.
From the introduced text:
AN ACT REQUIRING MEDICAID COVERAGE FOR FDA-APPROVED GENE THERAPIES TO TREAT SICKLE CELL DISEASE. Assembly convened: Section 1. (NEW) (Effective from passage) (a) The Commissioner of Social Services shall provide Medicaid coverage for gene therapies approved by the federal Food and Drug Administration to treat sickle cell disease. (b) The commissioner shall apply for any federal initiative to increase cost-effective access to the therapies, including, but not limited to, the Cell and Gene Therapy Access Model administered by the Centers for Medicare and Medicaid Services. (c) Not later than January 1, 2026, the commissioner shall file a report, in accordance with the provisions of section 11-4a of the general statutes, with the joint standing committee of the General Assembly having cognizance of matters relating to human services on the (1) efforts to increase cost-effective access to the therapies, (2) number of Medicaid recipients who have received Medicaid coverage for the therapies, (3) cost to the state to provide such therapies, and (4) estimated state LCO No. 5674 1 of Raised Bill No. 1473 appropriations needed to provide such coverage. This act shall take effect as follows and shall amend the following sections: Section 1 from passage New section Statement of Purpose: To require Medicaid coverage for gene therapies approved by the federal Food and Drug Administration to treat sickle cell …
Sponsors
- Sarah Keitt (D, 134) · primary sponsor
- Saud Anwar (D, 3)
- Patricia Miller (D, 27)
- Joan Hartley (D, 15)
- Matthew Lesser (D, 9)
- Kenneth Gucker (D, 138)
- Nicholas Gauthier (D, 38)
- Paul Cicarella (R, 34)
- Patricia Dillon (D, 92)
- John Kissel (R, 7)
Latest actions
- : Signed by the Governor
- : Transmitted to the Secretary of State
- : Transmitted by Secretary of the State to Governor
- : Public Act 25-63
- : House Passed
- : In Concurrence
- : Favorable Report, Tabled for the Calendar, House
- : House Calendar Number 526
- : Senate Passed
- : Reported Out of Legislative Commissioners' Office
Votes
- House Roll Call 265 (May 31, 2026): 142 yea, 0 nay, passed
- Senate Roll Call 105 (May 1, 2026): 36 yea, 0 nay, passed
- House Roll Call 265 (May 31, 2025): 142 yea, 0 nay, passed
- Senate Roll Call 105 (May 1, 2025): 36 yea, 0 nay, passed
Common questions
- What is SB1473?
- SB1473 is a bill in the Connecticut Legislature (2025 General Assembly): AN ACT REQUIRING MEDICAID COVERAGE FOR FDA-APPROVED GENE THERAPIES TO TREAT SICKLE CELL DISEASE.
- What does SB1473 do?
- In its own words: An act requiring medicaid coverage for fda-approved gene therapies to treat sickle cell disease. assembly convened.
- What is the status of SB1473?
- Chaptered as of June 23, 2025. Latest action: Signed by the Governor (June 23, 2025).
- Who sponsored SB1473?
- Sarah Keitt (D, 134), with 9 co-sponsors.
- Where is the official record for SB1473?
- On the Connecticut Legislature website: https://www.cga.ct.gov/asp/cgabillstatus/cgabillstatus.asp?selBillType=Bill&bill_num=SB01473&which_year=2025
Source: official Connecticut record. Tracked by Delilah, AI for legislation across all 50 states and Congress.